BioCentury | Nov 9, 2018
Company News

NICE recommends Jazz's Vyxeos for AML

...The U.K.'s NICE issued a final appraisal determination (FAD) recommending Vyxeos daunorubicin/cytarabine to treat adults with...
...acute myelogenous leukemia (AML) or AML with myelodysplasia-related changes. Vyxeos is a liposomal formulation of daunorubicin...
BioCentury | Nov 9, 2018
Company News

Earnings roundup: Alnylam off after first peek at Onpattro sales

...million in last year’s quarter but shy of the Street’s expectation of $482.7 million. Vyxeos daunorubicin/cytarabine...
BioCentury | Nov 7, 2018
Company News

Earnings roundup: Alnylam off after first peek at Onpattro sales

...million in last year’s quarter but shy of the Street’s expectation of $482.7 million. Vyxeos daunorubicin/cytarabine...
BioCentury | Aug 10, 2018
Company News

Jazz, MD Anderson partner to evaluate hematologic cancer therapies

...for hematologic malignancies, with an initial focus on evaluating and generating additional data for Vyxeos daunorubicin/cytarabine...
...in the U.S. to treat acute myelogenous leukemia (AML). Vyxeos is a liposomal formulation of daunorubicin...
BioCentury | Jul 13, 2018
Clinical News

EMA's CHMP recommends CAR Ts, rare disease therapies

...VII (MPS VII; Sly syndrome); Veyvondi vonicog alfa for von Willebrand disease (vWD); and Vyxeos daunorubicin/cytarabine...
...from Jazz Pharmaceuticals plc (NASDAQ:JAZZ) also has FDA approval. It is a liposomal formulation of daunorubicin...
...Products: Kymriah tisagenlecleucel, Yescarta axicabtagene ciloleucel, Cablivi caplicizumab, Mepsevii vestronidase alfa, Veyvondi vonicog alfa, Vyxeos daunorubicin/cytarabine...
BioCentury | Jun 29, 2018
Company News

CHMP backs CAR Ts, Orphan candidates

...VII (MPS VII; Sly syndrome); Veyvondi vonicog alfa for von Willebrand disease (vWD); and Vyxeos daunorubicin/cytarabine...
...from Jazz Pharmaceuticals plc (NASDAQ:JAZZ) also has FDA approval. It is a liposomal formulation of daunorubicin...
BioCentury | Mar 2, 2018
Clinical News

CHMP backs approval for Pfizer's AML triple combo

...EMA's CHMP recommended approval of Mylotarg gemtuzumab ozogamicin from Pfizer Inc. (NYSE:PFE) in combination with daunorubicin...
BioCentury | Feb 24, 2018
Company News

CHMP backs approval of Mylotarg, Alpivab, Kineret

...Nerlynx neratinib. The committee recommended approval of Mylotarg from Pfizer Inc. (NYSE:PFE) in combination with daunorubicin...
BioCentury | Dec 8, 2017
Company News

NICE does not recommend Novartis' Rydapt for AML

...newly diagnosed, FMS-like tyrosine kinase 3 (FLT3; CD135)-mutant acute myelogenous leukemia (AML) in combination with daunorubicin...
BioCentury | Nov 9, 2017
Clinical News

Novartis's Rydapt approved for AML, systemic mastocytosis in EU

...systemic mastocytosis with associated hematological neoplasm and mast cell leukemia. Rydapt in combination with standard daunorubicin...
Items per page:
1 - 10 of 191